'We have advised Perrigo that it failed to comply with #FDA postmarketing requirements for a study intended to determine the cardiovascular effects of testosterone replacement therapy product, Testosterone Gel, by the agreed upon deadline.'-FDA's Gotlieb
Benzinga Newsdesk